Corporate | 2 November 2009 08:00
4SC AG / Miscellaneous
02.11.2009
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
4SC AG
Q3 Conference Call and Webcast
6 November 2009
Planegg-Martinsried, Germany, 2 November, 2009 - 4SC AG (Frankfurt, Prime
Standard: VSC) a drug discovery and development company, will announce its
financial results for the third quarter (ended 30 September, 2009) on 6
November, 2009. The senior management team will host a conference call at
3pm CET (10am EST) on the day to inform about the financial results for the
quarter and all important developments in the reporting period.
Access to the presentation slides can be obtained at:
http://www.cyber-presentation.de/cgi-bin/visitors.ssp?fn=visitor&id=1092
Date:
6 November, 2009
Time:
3pm CET (10am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800 358 0886 (UK)
+1 877 941 2928 (USA)
+49 6103 485 3002 (other countries)
Conference ID:
4179961
Approximately two hours after the live presentation, an audio replay of the
conference will be available on the 'investors' section of the homepage
www.4sc.com.
For further information please contact:
Yvonne Alexander
Investor & Public Relations
4SC AG
Tel.: +49 (0) 89 70 07 63 - 66
yvonne.alexander@4sc.com
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development Company
focused on autoimmune and cancer indications. The Company currently has
three clinical programs, with three further clinical trials planned to
commence in 2009. 4SC-101, a small molecule, is in a Phase IIb study in
rheumatoid arthritis as well as in a Phase IIa exploratory study in Crohn's
disease. The company's lead oncology compound, 4SC-201, a histone
deacetylase (HDAC) inhibitor, is in a Phase II trial in hepatocellular
carcinoma and is due to commence a further Phase II trial in Hodgkin's
lymphoma in 2009. Drug candidates are developed until proof-of-concept in
order to generate value creating partnerships with the pharmaceutical
industry in return for advance and milestone payments as well as royalties.
4SC was founded in 1997, has 92 employees, and is listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005. For further
information please visit www.4sc.com.
02.11.2009 Financial News transmitted by DGAP
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------